Autopoiesis Sciences Bets $11M That Science's Missing Data Is Its Discarded Ideas

Scientific discovery does not come with unit tests. A proof can be checked and code can be run, but a frontier research question may have no known answer, no cheap experiment, and no clean signal telling a scientist when to keep going or walk away.

Autopoiesis Sciences has raised an $11M Seed round around that missing control problem. Threshold Ventures led the financing, with Informed Ventures, Alpaca VC, VitalStage Ventures, Correlation Ventures, DarkMode Ventures, Mike Mahlkow, Cross Atlantic Angels, Max Keller, JD Montgomery, Adam Grosser, and others participating. The company announced the round on September 30, 2026. It did not disclose a valuation, audited revenue, a detailed hiring target, or a verified total-funding figure beyond the current $11M round.

The San Francisco company, founded in 2025, builds AI systems designed to support and eventually conduct long-horizon scientific inquiry. Its thesis is unusually specific: the published record preserves results more reliably than it preserves the judgment that produced them. Autopoiesis wants to capture those abandoned hypotheses, challenged assumptions, failed searches, and changes of direction, then use that process to help models decide how to reason while an investigation is still moving. The company said the capital will help grow the team, expand its research, and advance AI systems capable of autonomous scientific discovery.

The founding team spans several sides of the problem. Joseph Reth is co-founder and CEO. Dr. Eike Gerhardt is a co-founder with experience across academic research, venture capital, and company building. Dr. Lawrence Callahan is a co-founder and Chief Scientist whose public record includes decades of scientific work involving the FDA and NIH.

Autopoiesis first built Aristotle, an AI research partner for literature review, hypothesis generation, analysis, and experimental design. The company says thousands of researchers across institutions including Pfizer, the FDA, Harvard, GSK, Merck, MIT, AstraZeneca, Stanford, Johnson & Johnson, the NIH, Bristol Myers Squibb, the European Medicines Agency, Oxford, Yale, and Johns Hopkins use the system. Those institutional names require careful accounting: they describe company-reported usage by researchers affiliated with the named organizations, not evidence that every institution is a customer, procurement partner, or endorser.

The more interesting asset may be the interaction record Aristotle creates. A normal paper compresses the research path into a legible result; Aristotle can retain the discarded branches, weak evidence, revisions, and timing of decisions that occurred before the result. The company says it collected 3.5M reasoning hours of scientific-judgment data through that work.